Immunomedics (IMMU) 3.96 $IMMU
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position
Business Wire - Thu Apr 10, 11:05AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) common stock between May 9, 2013 and October 9, 2013.
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Dr. David M. Goldenberg, Founder and Chairman of the Board, and Cynthia L. Sullivan, President and Chief Executive Officer, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Wednesday, April 23, 2014, in honor of the Company's 30-year uninterrupted listing on the NASDAQ Stock Market. Following the Opening Bell Ceremony, the Company will host a R&D day at the NASDAQ MarketSite.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Immunomedics, Inc.
Business Wire - Tue Apr 08, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" , have until April 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer
GlobeNewswire - Tue Apr 08, 8:39AM CDT
/p>
Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 08, 8:21AM CDT
Let's take a look at four stocks -- Takeda , Eli Lilly , Immunomedics , and Pharmacyclics -- which could make waves in the health care sector this morning. Takeda and Eli Lilly ordered to pay $9 billion for Actos cancer risks ...
Immunomedics Reports Results From Three Phase I Trials With IMMU-130 in Metastatic Colorectal Cancer
GlobeNewswire - Mon Apr 07, 10:01AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the results from 3 Phase I trials with IMMU-130, the Company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate (ADC) was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer (mCRC) than when administered every other week.
Immunomedics Announces Multiple Partial Responses With IMMU-132 in Solid Cancers
GlobeNewswire - Mon Apr 07, 10:00AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 5 patients reported a partial response as their best response, based on RECIST 1.1 criteria, in the Company's ongoing Phase I/II clinical trial of its investigational antibody-drug conjugate (ADC), IMMU-132, in patients with solid cancers. IMMU-132 is an anti-TROP-2 antibody with SN-38, the active metabolite of irinotecan, linked to the antibody.
Investors look to Lighten Up on Shares of Immunomedics, Shares Down 5.8% (IMMU)
Comtex SmarTrend(R) - Thu Apr 03, 12:46PM CDT
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 5.8% to $4.14 on 1.1x average daily volume. Immunomedics has traded 872,000 shares thus far today, vs. average volume of 813,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's -0.1%) and underperformed the S&P 500 (-5.8% to the S&P's -0.2%) during today's trading.
Immunomedics to Provide Clinical Trial Updates on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference
GlobeNewswire - Mon Mar 31, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 - 9, 2014.
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Immunomedics, Inc.
Business Wire - Fri Mar 28, 8:52AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Immunomedics, Inc. ("IMMU" or the "Company" and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
EQUITY ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Class Action Deadline -- IMMU
GlobeNewswire - Wed Mar 26, 7:04PM CDT
The Rosen Law Firm, P.A. reminds purchasers of the common stock of Immunomedics, Inc. (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013 of the important April 28, 2014 lead plaintiff deadline in the class action.
INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced By Glancy Binkow & Goldberg LLP
Business Wire - Tue Mar 25, 9:32AM CDT
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has filed in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" .
Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
M2 - Fri Mar 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tp6b8p/diffuse_large) has announced the addition of the Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 report to their offering. Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: Table of Contents Table of Contents List of Tables List of Figures Introduction Diffuse Large B-Cell Lymphoma Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Diffuse Large B-Cell Lymphoma Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma Clinical Trial Profiles Clinical Trial Overview of Top Companies F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Celgene Corporation Clinical Trial Overview of Celgene Corporation Amgen Inc. Clinical Trial Overview of Amgen Inc. Novartis AG Clinical Trial Overview of Novartis AG Takeda Pharmaceutical Company Limited Clinical Trial Overview of Takeda Pharmaceutical Company Limited Pharmacyclics, Inc. Clinical Trial Overview of Pharmacyclics, Inc. GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Bayer AG Clinical Trial Overview of Bayer AG AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Immunomedics, Inc. Clinical Trial Overview of Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government National Cancer Institute Clinical Trial Overview of National Cancer Institute Fred Hutchinson Cancer Research Center Clinical Trial Overview of Fred Hutchinson Cancer Research Center Groupe d'Etudes de Lymphomes de L'Adulte Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte Mayo Clinic Clinical Trial Overview of Mayo Clinic The University of Texas M. D. Anderson Cancer Center Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center FUDAN University Clinical Trial Overview of FUDAN University Memorial Sloan Kettering Cancer Center Clinical Trial Overview of Memorial Sloan Kettering Cancer Center The Lymphoma Academic Research Organisation Clinical Trial Overview of The Lymphoma Academic Research Organisation Massachusetts General Hospital Clinical Trial Overview of Massachusetts General Hospital Stanford University Clinical Trial Overview of Stanford University Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014- List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014- Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/tp...fuse_large About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position -- IMMU
GlobeNewswire - Thu Mar 20, 5:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company" (Nasdaq:IMMU) common stock between May 9, 2013 and October 9, 2013.
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Immunomedics, Inc. to Contact Brower Piven Before the April 28, 2014 Lead Plaintiff Deadline -- IMMU
GlobeNewswire - Wed Mar 19, 7:30PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. ("Immunomedics" or the "Company" (Nasdaq:IMMU) common stock during the period between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" .
Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. and NII Holdings, Inc.
PR Newswire - Tue Mar 18, 3:01PM CDT
CytRx Corporation
INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Mar 18, 9:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" .
The Rosen Law Firm Announces Class Action Charging Securities Violations Against Immunomedics, Inc. -- IMMU
GlobeNewswire - Tue Mar 11, 12:19PM CDT
The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of purchasers of the common stock of Immunomedics, Inc. (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013.
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position
Business Wire - Thu Apr 10, 11:05AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) common stock between May 9, 2013 and October 9, 2013. Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Immunomedics to Ring Opening Bell and Host R&D Day at the NASDAQ Stock Market
GlobeNewswire - Thu Apr 10, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Dr. David M. Goldenberg, Founder and Chairman of the Board, and Cynthia L. Sullivan, President and Chief Executive Officer, will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York City, on Wednesday, April 23, 2014, in honor of the Company's 30-year uninterrupted listing on the NASDAQ Stock Market. Following the Opening Bell Ceremony, the Company will host a R&D day at the NASDAQ MarketSite.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Immunomedics, Inc.
Business Wire - Tue Apr 08, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" , have until April 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer
GlobeNewswire - Tue Apr 08, 8:39AM CDT
/p>
Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics
Leo Sun, The Motley Fool - Motley Fool - Tue Apr 08, 8:21AM CDT
Let's take a look at four stocks -- Takeda , Eli Lilly , Immunomedics , and Pharmacyclics -- which could make waves in the health care sector this morning. Takeda and Eli Lilly ordered to pay $9 billion for Actos cancer risks ...
Immunomedics Reports Results From Three Phase I Trials With IMMU-130 in Metastatic Colorectal Cancer
GlobeNewswire - Mon Apr 07, 10:01AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the results from 3 Phase I trials with IMMU-130, the Company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate (ADC) was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer (mCRC) than when administered every other week.
Immunomedics Announces Multiple Partial Responses With IMMU-132 in Solid Cancers
GlobeNewswire - Mon Apr 07, 10:00AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 5 patients reported a partial response as their best response, based on RECIST 1.1 criteria, in the Company's ongoing Phase I/II clinical trial of its investigational antibody-drug conjugate (ADC), IMMU-132, in patients with solid cancers. IMMU-132 is an anti-TROP-2 antibody with SN-38, the active metabolite of irinotecan, linked to the antibody.
Investors look to Lighten Up on Shares of Immunomedics, Shares Down 5.8% (IMMU)
Comtex SmarTrend(R) - Thu Apr 03, 12:46PM CDT
Immunomedics (NASDAQ:IMMU) is one of today's worst performing low-priced stocks, down 5.8% to $4.14 on 1.1x average daily volume. Immunomedics has traded 872,000 shares thus far today, vs. average volume of 813,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's -0.1%) and underperformed the S&P 500 (-5.8% to the S&P's -0.2%) during today's trading.
Immunomedics to Provide Clinical Trial Updates on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference
GlobeNewswire - Mon Mar 31, 7:30AM CDT
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 - 9, 2014.
Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Immunomedics, Inc.
Business Wire - Fri Mar 28, 8:52AM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Immunomedics, Inc. ("IMMU" or the "Company"
and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. EQUITY ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Class Action Deadline -- IMMU
GlobeNewswire - Wed Mar 26, 7:04PM CDT
The Rosen Law Firm, P.A. reminds purchasers of the common stock of Immunomedics, Inc. (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013 of the important April 28, 2014 lead plaintiff deadline in the class action.
INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced By Glancy Binkow & Goldberg LLP
Business Wire - Tue Mar 25, 9:32AM CDT
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has filed in the United States District Court for the District of New Jersey on behalf of a class (the "Class"
comprising all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" . Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
M2 - Fri Mar 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tp6b8p/diffuse_large) has announced the addition of the Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 report to their offering. Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: Table of Contents Table of Contents List of Tables List of Figures Introduction Diffuse Large B-Cell Lymphoma Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Diffuse Large B-Cell Lymphoma Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma Clinical Trial Profiles Clinical Trial Overview of Top Companies F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Celgene Corporation Clinical Trial Overview of Celgene Corporation Amgen Inc. Clinical Trial Overview of Amgen Inc. Novartis AG Clinical Trial Overview of Novartis AG Takeda Pharmaceutical Company Limited Clinical Trial Overview of Takeda Pharmaceutical Company Limited Pharmacyclics, Inc. Clinical Trial Overview of Pharmacyclics, Inc. GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Bayer AG Clinical Trial Overview of Bayer AG AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Immunomedics, Inc. Clinical Trial Overview of Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government National Cancer Institute Clinical Trial Overview of National Cancer Institute Fred Hutchinson Cancer Research Center Clinical Trial Overview of Fred Hutchinson Cancer Research Center Groupe d'Etudes de Lymphomes de L'Adulte Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte Mayo Clinic Clinical Trial Overview of Mayo Clinic The University of Texas M. D. Anderson Cancer Center Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center FUDAN University Clinical Trial Overview of FUDAN University Memorial Sloan Kettering Cancer Center Clinical Trial Overview of Memorial Sloan Kettering Cancer Center The Lymphoma Academic Research Organisation Clinical Trial Overview of The Lymphoma Academic Research Organisation Massachusetts General Hospital Clinical Trial Overview of Massachusetts General Hospital Stanford University Clinical Trial Overview of Stanford University Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014- List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014- Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/tp...fuse_large About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Involving IMMUNOMEDICS, INC. and Its Board of Directors and a Deadline of April 28, 2014 to Seek a Lead Plaintiff Position -- IMMU
GlobeNewswire - Thu Mar 20, 5:05PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) common stock between May 9, 2013 and October 9, 2013. SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Immunomedics, Inc. to Contact Brower Piven Before the April 28, 2014 Lead Plaintiff Deadline -- IMMU
GlobeNewswire - Wed Mar 19, 7:30PM CDT
Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) common stock during the period between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" . Lifshitz & Miller Law Firm Announces Investigation of CytRx Corporation, DURECT Corporation, Hastings Entertainment, Inc., Immunomedics, Inc. and NII Holdings, Inc.
PR Newswire - Tue Mar 18, 3:01PM CDT
CytRx Corporation
INVESTOR ALERT: Class Action Lawsuit Against Immunomedics, Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Mar 18, 9:32AM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of the common stock of Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the "Class Period" . The Rosen Law Firm Announces Class Action Charging Securities Violations Against Immunomedics, Inc. -- IMMU
GlobeNewswire - Tue Mar 11, 12:19PM CDT
The Rosen Law Firm, P.A. today announced that a class action lawsuit has been filed on behalf of purchasers of the common stock of Immunomedics, Inc. (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013.
